Beijing Zheyuan Technology

Beijing Zheyuan Technology is a biotechnology company specializing in computational medicine and AI-driven drug discovery. The company utilizes its proprietary Digital Twin platform to simulate disease biology and drug responses, with a primary focus on precision oncology. By integrating multi-omics data with advanced machine learning algorithms, Zheyuan identifies novel therapeutic targets and biomarkers to enhance the efficiency of drug development. Their platform is designed to predict clinical outcomes and optimize patient stratification, aiming to reduce the high failure rates associated with traditional clinical trials. The company is a spin-off from the Chinese Academy of Sciences and maintains strong academic and clinical partnerships to validate its computational insights.